|
End-of-day quote
Taiwan S.E.
2026-10-30
|
5-day change | 1st Jan Change | ||
| 204.00 TWD | +0.74% |
|
+0.74% | +82.96% |
| 10-30 | TAHO Pharmaceuticals Partner Files NDA for Pediatric TAH4411 Indication | MT |
| 10-26 | TAHO Pharmaceuticals Sued Over Patent Infringement in US | MT |
| Market Cap | 10.69B 328M 293M 270M 245M 457M 31.11B 466M 3.22B 1.29B 16.37B 1.23B 1.2B 51.61B | P/E 2024 |
-12x | P/E 2025 | -26.8x |
|---|---|---|---|---|---|
| Enterprise Value | 10.31B 316M 283M 260M 236M 441M 30.01B 449M 3.1B 1.25B 15.79B 1.19B 1.16B 49.78B | EV / Sales 2024 |
-
| EV / Sales 2025 | 636x |
| Free-Float |
84.77% | Yield 2024 * |
-
| Yield 2025 | - |
| 1 day | +0.74% | ||
| 1 week | +0.74% | ||
| 1 month | -15.35% | ||
| 3 months | +82.96% | ||
| 6 months | +70.71% | ||
| Current year | +82.96% |
| 1 week | 190 |  | 228.5 |
| 1 month | 168 | | 237.5 |
| Current year | 100.5 | | 302 |
| 1 year | 100.5 | | 302 |
| 3 years | 32.25 | | 302 |
| 5 years | 32.25 | | 302 |
| 10 years | 1.9 | | 302 |
| Manager | Title | Age | Since |
|---|---|---|---|
Howard Lee
CEO | Chief Executive Officer | 64 | 2014-03-09 |
Frank Tung
IRC | Investor Relations Contact | - | - |
| Director | Title | Age | Since |
|---|---|---|---|
Howard Lee
CHM | Chairman | 64 | 2014-03-09 |
Ming Wei Chiang
BRD | Director/Board Member | - | 2012-10-30 |
I Te Huang
BRD | Director/Board Member | - | 2012-10-30 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +0.74% | +0.74% | +27.90% | +8,769.57% | 328M | |
| +3.19% | +11.31% | +64.28% | +155.91% | 1,263B | |
| -0.73% | +3.56% | +44.65% | +84.17% | 658B | |
| +1.41% | +3.24% | +35.25% | +108.88% | 521B | |
| +0.42% | +3.20% | +55.81% | +72.50% | 391B | |
| +2.18% | +2.93% | +73.90% | +45.59% | 369B | |
| +1.12% | +4.52% | +34.76% | +58.24% | 307B | |
| +6.96% | +8.86% | +11.95% | +36.20% | 290B | |
| +1.15% | +6.09% | +56.15% | +82.25% | 252B | |
| +3.06% | +9.38% | +42.48% | +117.32% | 212B | |
| Average | +1.95% | +5.38% | +44.71% | +953.06% | 426.23B | |
| Weighted average by Cap. | +2.01% | +6.60% | +50.51% | +101.10% |
| 2024 | 2025 | |
|---|---|---|
| Net sales | - | 8.41M 258K 231K 212K 192K 360K 24.47M 366K 2.53M 1.02M 12.87M 967K 947K 40.6M |
| Net income | -167M -5.13M -4.6M -4.23M -3.83M -7.16M -487M -7.29M -50.41M -20.24M -256M -19.26M -18.85M -808M | -214M -6.57M -5.88M -5.41M -4.9M -9.17M -624M -9.34M -64.55M -25.91M -328M -24.66M -24.13M -1.03B |
| Net Debt | -479M -14.69M -13.15M -12.1M -10.96M -20.49M -1.39B -20.88M -144M -57.92M -734M -55.12M -53.94M -2.31B | -379M -11.6M -10.39M -9.56M -8.66M -16.19M -1.1B -16.49M -114M -45.77M -580M -43.55M -42.63M -1.83B |
Employees
35
Sector
Pharmaceuticals
| Date | Price | Change | Volume |
|---|---|---|---|
| 26-10-30 | NT$204.00 | +0.74% | 404,575 |
| 26-10-29 | NT$202.50 | -8.16% | 827,829 |
| 26-10-28 | NT$220.50 | +8.35% | 822,233 |
| 26-10-27 | NT$203.50 | +0.49% | 1,155,012 |
- Stock Market
- Stocks
- 6467 Stock
Select your edition
All financial news and data tailored to specific country editions
